Certain genetic testing, such as XPG genetic testing, may be used as a predictor of individualized NSCLC treatment strategies [4]. Currently, PD-1/PDL-1 monoclonal antibody is widely used in the treatment of lung cancer [5]. For example, PD-1/PDL-1 monoclonal antibody is used in combination with conventional chemotherapeutics to treat advanced non-small cell lung cancer, which has achieved certain therapeutic value. The specific details are reported as follows:
正在翻译中..